|Trial denomination||Objective||Endpoint||ClinicalTrials.gov Identifier|
|Indapamide versus hydrochlorothiazide in elderly hypertensive patients with renal insufficiency||Evaluate the effects of indapamide SR 1.5 mg on renal function, endothelial function, blood pressure variability by comparison with hydrochlorothiazide 25 mg, in patients with mild-to-moderate renal insufficiency and hypertension.||Primary outcome measures: renal function |
Secondary outcome measures: endothelial function, blood pressure variability
|Compare the effects of Lercanidipine Hydrochloride Tablet (Zanidip) and Felodipine sustained-release tablet for Hypertension||Compare felodipine sustained-release tablets to Lercanidipine hydrochloride tablets (Zanidip ) for the treatment of patients with mild-to-moderate primary hypertension and to investigate the influence on patients’ heart rate and blood pressure variability.||Primary outcome measures: change from baseline in mean seated diastolic BP in clinical after 6 weeks of treatment |
Change from baseline in mean seated systolic BP after 6 weeks of treatment
|ARB and CCB longest combination treatment on ambulatory and home BP in hypertension with atrial fibrillation-multicenter study on time of Dosing (ACROBAT)||Evaluate of 24-hour antihypertensive effect of long-acting ARB-CCB tablet administrated to hypertensive patients with atrial fibrillation, and comparison of 24-hour antihypertensive effect of long-acting ARB-CCB tablet between morning administration and bedtime administration.||Primary outcome measures: change in 24-hour average BP from baseline to week 12. |
Secondary outcome measures:
Change in BP at nighttime, early-morning, and daytime from baseline to Week 12.
Change in BPV from baseline to Week 12.
|Renal sympathetic modification in patients with metabolic syndrome||Assess the incident of composite cardiovascular events after renal sympathetic modification using THERMOCOOL catheter in patients with metabolic syndrome, and evaluate safety and efficacy of the intervention.||Primary outcome measures: composite cardiovascular events (myocardial infarction, heart failure, sudden death, cardiogenic death) |
Secondary outcome measures: effect on glucose and lipid metabolism and BPV
|Comparison of bisoprolol with metoprolol succinate sustained-release on heart rate and blood pressure in hypertensive patients (CREATIVE)||Demonstrate the superiority and/or noninferiority of bisoprolol on metoprolol succinate sustained-release (SR)||Primary outcome measures: change of mean diastolic ABPM in the last 4 hours after 12-week treatment from baseline. |
Secondary outcome measures: change of mean ambulatory 24 h, daytime and nighttime BP
24-hour variability of BP